CME Group
CME
$308.06
+0.77%
CME Group operates the world's largest derivatives marketplace, providing futures and options trading and clearing across interest rates, equity indexes, foreign currencies, energy, metals, and agricultural commodities, alongside market data and collateral optimization services through its 2018 NEX acquisition and a 27% stake in S&P Dow Jones Indices. It is the dominant, near-monopoly infrastructure player in global futures — a network-effect business where liquidity attracts liquidity, making it the venue of record for benchmark interest-rate and S&P 500 hedging rather than a disruptor or niche challenger. The current investor narrative centers on whether CME can sustain record trading volumes and roughly 60%+ net margins as the Fed embarks on a renewed rate-hike cycle (with a near-certain December 2026 hike and rising odds of multiple hikes through 2027), which historically drives volatility, hedging demand, and clearing-fee revenue higher. That macro tailwind is being weighed against a stretched valuation, a stock that has round-tripped a sharp mid-year drawdown, and a split analyst community that debates whether peak volatility is already priced in.…
CME
CME Group
$308.06
Related headlines
Investment Opinion: Should I buy CME Today?
Rating: Hold. CME is a high-quality infrastructure monopoly with a 61% net margin and 4% dividend yield, but the current valuation of 24.4x trailing PE and 15.1x PS already reflects its strengths, and the average analyst target of $313.81 offers only 2.6% upside. The consensus recommendation of "buy" (mean 2.41) is tempered by recent downgrades and a wide target range ($227-$367), suggesting balanced risk/reward at $305.71.
Supporting evidence: Revenue growth has decelerated to 0.84% YoY in Q2 2026, well below the historical pace, while margins are compressing (gross margin 69.25% vs. 88.14% in Q1). Free cash flow remains robust at $4.21 billion TTM, and the balance sheet is fortress-like with debt-to-equity of 0.119. However, the 15x sales multiple is rich for a business with near-zero growth, and the 97.2% payout ratio limits financial flexibility. The implied upside to the average target is thin, and the stock trades near the upper end of its historical PE band.
Risks and conditions: The biggest risks are a normalization in trading volumes, further margin compression, and a valuation de-rating. This Hold would upgrade to Buy if revenue growth accelerates above 5% or if the PE compresses below 20x (around $250), providing a better entry point. It would downgrade to Sell if gross margins fall below 65% or if the Fed signals a pause, undermining the volume thesis. Relative to its history and peers, CME appears fairly valued to slightly overvalued, with the market pricing in optimistic expectations for sustained volatility.
Sign up to view all
CME 12-Month Price Forecast
CME is a high-quality franchise with a wide moat and exceptional profitability, but the current valuation leaves little margin of safety. The stock has rallied 12.89% in the past month, outperforming SPY by 13.91%, and now sits just 7.7% below its 52-week high. While the Fed hiking cycle provides a tailwind, revenue growth is stagnant and margins are compressing, creating a balanced risk/reward. The analyst consensus is moderately bullish but with a wide target range, reflecting uncertainty. I would upgrade to bullish if revenue growth accelerates above 5% or if the stock pulls back to the $250-$270 range, and downgrade to bearish if gross margins fall below 65% or if the Fed signals a pause.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CME Group's 12-month outlook, with a consensus price target around $316.00 and implied upside of +2.6% versus the current price.
Average Target
$316.00
0 analysts
Implied Upside
+2.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$227 - $367
Analyst target range
CME is covered by 16 analysts with a consensus recommendation of "buy" (mean rating 2.41 on a scale where lower is more bullish), and an average target price of $313.81 — implying roughly +2.6% upside from the current $305.71, a thin margin that suggests the stock is already trading close to fair value in the eyes of the Street. The consensus is moderately bullish but not conviction-driven: the average target sits just 2.6% above spot, and the recommendation mean of 2.41 is closer to Hold than to a strong Buy, reflecting the debate over whether peak volatility and record volumes are already reflected in the price. The target range is wide — from a low of $227.00 (about -25.7% downside) to a high of $367.00 (about +20.0% upside) — a spread of $140, or roughly 46% of the current price, which signals meaningful disagreement about the durability of the volume-driven earnings cycle. The high target of $367 likely assumes a sustained Fed hiking cycle that keeps volatility and hedging demand elevated, driving transaction-fee revenue and multiple expansion; the low target of $227 likely prices in volatility normalization, margin compression from the Q2 gross-margin dip to 69.25%, and a return to the June 2026 drawdown lows. Institutional ratings show a split tape: TD Cowen reiterated Buy twice (September 3 and September 28, 2026), Morgan Stanley and Piper Sandler remain Overweight, but Deutsche Bank downgraded from Buy to Hold on August 19, 2026, and both JP Morgan (Underweight) and B of A Securities (Underperform) maintain bearish stances — a pattern of recent downgrades and persistent bears that tempers the bullish consensus and suggests the risk/reward is balanced rather than compelling at current levels.
Bulls vs Bears: CME Investment Factors
The bull case rests on CME's unmatched liquidity moat, elite 61% net margins, fortress balance sheet, and a Fed rate-hike cycle that should drive volatility and transaction volumes. The bear case centers on stagnant 0.84% revenue growth, margin compression, a stretched 24.4x PE and 15.1x PS, and only 2.6% upside to analyst targets. Currently, the bear evidence appears slightly stronger given the valuation premium relative to growth and the recent margin deterioration, though the macro tailwind could quickly shift momentum. The single most important tension is whether the renewed rate-hike cycle will sustainably lift trading volumes and clearing fees enough to justify the premium multiple, or whether peak volatility is already priced in. Resolution of this debate—likely through Q3 volume data and Fed policy trajectory—will determine the stock's direction.
Bullish
- Unmatched Liquidity Moat: CME operates the world's largest derivatives marketplace, with a 27% stake in S&P Dow Jones Indices making it the exclusive venue for S&P futures. This network-effect business attracts liquidity that begets more liquidity, creating a near-monopoly in benchmark interest-rate and equity-index hedging that is extremely difficult to replicate.
- Elite Profitability and Cash Generation: Q2 2026 net income was $1.042 billion on $1.706 billion of revenue, a 61.1% net margin, with TTM free cash flow of $4.21 billion. Operating margin of 64.86% and gross margin of 86.09% (TTM) are exceptional even by exchange-industry standards, funding a 4.00% dividend yield and $698.2 million in Q2 buybacks.
- Fortress Balance Sheet: Debt-to-equity is just 0.119 and the current ratio is 1.03, with essentially no external financing dependence. The capital-light exchange model generates ample internal cash to cover the 97.2% payout ratio and still repurchase shares, minimizing financial risk.
- Fed Rate-Hike Tailwind: A near-certain December 2026 rate hike and rising odds of multiple hikes through 2027 (35% chance of at least four hikes by September 2027) historically drive volatility, hedging demand, and clearing-fee revenue higher. This macro backdrop supports CME's transaction-driven revenue, which is 79% of the top line.
Bearish
- Stagnant Revenue Growth: Q2 2026 revenue grew just 0.84% year-over-year to $1.706 billion, and the quarterly sequence shows a mild downtrend from Q1 2026's $1.880 billion. With 79% of revenue from transaction fees, the top line is highly cyclical and volume-dependent, leaving little room for error at a premium valuation.
- Margin Compression: Q2 2026 gross margin of 69.25% is down sharply from Q1 2026's 88.14% and Q2 2025's 86.90%, while net margin of 61.06% is below Q1 2026's 61.40% and Q4 2025's 70.84%. This suggests cost pressure or revenue-mix dilution is eroding the historically pristine margin profile.
- Stretched Valuation: At 24.43x trailing PE and 15.06x PS, CME trades at a premium to the broad financial sector and near the upper end of its multi-year PE band (which bottomed near 19.3x in Q2 2026). The 15x sales multiple is aggressive for a business growing revenue at under 1%.
- Thin Analyst Upside: The average analyst target of $313.81 implies only +2.6% upside from $305.71, and the recommendation mean of 2.41 is closer to Hold than a strong Buy. Recent downgrades (Deutsche Bank to Hold on August 19, 2026) and persistent bears (JP Morgan Underweight, B of A Underperform) signal balanced risk/reward.
CME Technical Analysis
CME is in a sustained uptrend that has fully recovered from a severe mid-year drawdown: the stock is up 13.69% over the past year and 13.36% year-to-date, and at $305.71 it sits at roughly 79% of its 52-week range (52-week low $218.31, 52-week high $329.16). That positioning — well above the midpoint but still about 7% below the high — signals constructive momentum without the overextension of a fresh all-time-high breakout, and the fact that the 1-year gain modestly outpaces SPY's 13.13% confirms the stock is a relative performer rather than a laggard. The path was volatile: the stock fell from a May peak near $305 to a June trough of $218.58 (a max drawdown of -33.05%), then rebuilt the entire decline over the following four months. Recent momentum is decisively accelerating: the stock is up 12.89% over the past month versus a -1.02% decline for SPY (a +13.91% relative-strength spread) and up 19.74% over three months versus SPY's +2.85% (+16.89% relative strength), while the 6-month gain of just 7.24% confirms the V-shaped recovery rather than a steady climb. This 1-month surge is a sharp reversal of the June downtrend and reflects a powerful mean-reversion-plus-catalyst move; the 3-month relative strength of +16.89% is the strongest signal in the dataset and suggests institutional accumulation, though such a steep one-month advance (+12.89%) raises near-term overbought risk absent RSI confirmation (RSI data not available). Key levels are clear: resistance sits at the 52-week high of $329.16, roughly 7.7% above the current $305.71, and a breakout above that level would confirm a new leg higher and likely trigger momentum-chasing flows; support rests at the 52-week low of $218.31, about 28.6% below current price, with intermediate support around the $260-$270 consolidation zone from August-September. The stock's beta of just 0.27 is a critical risk-management feature — CME is roughly 73% less volatile than SPY, meaning it behaves defensively in sell-offs and requires larger position sizing to achieve equivalent market exposure, which is consistent with its role as a low-beta, cash-generative infrastructure asset rather than a high-beta trading vehicle.
Beta
0.27
0.27x market volatility
Max Drawdown
-33.0%
Largest decline past year
52-Week Range
$218-$329
Price range past year
Annual Return
+14.3%
Cumulative gain past year
| Period | CME Return | S&P 500 |
|---|---|---|
| 1m | +16.5% | -0.8% |
| 3m | +18.5% | +3.3% |
| 6m | +7.2% | +7.6% |
| 1y | +14.3% | +13.0% |
| ytd | +14.2% | +12.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CME Fundamental Analysis
Revenue growth has decelerated to a crawl: Q2 2026 revenue of $1.706 billion grew just 0.84% year-over-year against Q2 2025's $1.692 billion, and the quarterly sequence shows a mild downtrend from Q1 2026's $1.880 billion and Q4 2025's $1.649 billion, with the current quarter below the year-ago Q1 2025 figure of $1.642 billion on a sequential basis. The revenue mix is overwhelmingly transaction-driven — clearing and transaction fees of $1.353 billion dwarf market data at $238.1 million and other revenue at $115.6 million — meaning CME's top line is highly levered to trading volumes and volatility rather than recurring subscription revenue, which explains the flat growth despite a volatile macro backdrop. The near-zero 0.84% YoY growth is the key tension in the investment case: the company's earnings power is enormous but its growth is volume-dependent and cyclical, so the market is effectively paying a premium for a business whose revenue is currently stagnating. Profitability remains elite: Q2 2026 net income was $1.042 billion on $1.706 billion of revenue (a 61.1% net margin), gross margin was 69.25% in the quarter and 86.09% on a TTM basis, and operating margin was 64.86% — margins that are exceptional even by exchange-industry standards, where 50-60% operating margins are typical for scaled venues. However, the margin trajectory is compressing: Q2 2026 gross margin of 69.25% is down sharply from Q1 2026's 88.14% and Q2 2025's 86.90%, and net margin of 61.06% is below Q1 2026's 61.40% and Q4 2025's 70.84%, suggesting cost pressure or revenue-mix dilution is eroding the historically pristine margin profile. The balance sheet is fortress-like: debt-to-equity is just 0.119, the current ratio is 1.03, and TTM free cash flow is $4.21 billion against a $98.2 billion market cap, with Q2 2026 free cash flow of $923.5 million and operating cash flow of $947.1 million. ROE of 14.08% and ROA of 1.52% reflect the capital-light but heavily levered (via customer collateral) exchange model, and the company comfortably funds its dividend (payout ratio 97.2%, dividend yield 4.00%) and buybacks ($698.2 million repurchased in Q2 2026) from internal cash generation — external financing dependence is essentially nil, and the low debt load means financial risk is minimal.
Quarterly Revenue
$1.7B
2026-06
Revenue YoY Growth
+0.8%
YoY Comparison
Gross Margin
69.3%
Latest Quarter
Free Cash Flow
$4.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CME Overvalued?
Because CME is solidly profitable (Q2 2026 net income of $1.042 billion), the PE ratio is the appropriate primary metric: the stock trades at a trailing PE of 24.43x and a forward PE of 23.13x, a modest 5.3% compression that implies the market expects only modest earnings growth — consistent with the 0.84% revenue growth and analyst consensus EPS of $16.90 against a $305.71 price. The gap between trailing and forward multiples is unusually narrow for a high-quality compounder, signaling that the market is not pricing in an acceleration and that valuation support depends on earnings stability rather than growth re-rating. On a price-to-sales basis the stock looks far richer at 15.06x (TTM) and 15.85x EV/Sales, with EV/EBITDA at 16.83x — multiples that reflect the 61% net margin and 86% gross margin but leave little room for disappointment. Peer comparison is constrained by the absence of a formal industry-average dataset, but CME's 24.4x trailing PE and 15.1x PS sit at a premium to the broad financial-services sector and are broadly in line with scaled exchange peers such as ICE and Cboe, which typically trade in the low-to-mid-20s on earnings; the premium is justified by CME's unmatched liquidity moat, 61% net margin, and 4.0% dividend yield, but the 15x sales multiple is aggressive for a business growing revenue at under 1%. Against its own history, the current 24.43x PE is above the 2024-2025 range (which bottomed near 19.3x in Q2 2026 and 21.0x in Q4 2025) and near the upper end of its multi-year band, while the 15.06x PS is well below the 46-63x historical PS readings (which were distorted by the pre-2026 share-count/collateral accounting) — the PE signal is the more reliable one, and it suggests the market is pricing in optimistic expectations relative to the company's current growth trajectory.
PE
24.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~28x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are moderate but centered on revenue concentration and margin pressure. Transaction fees account for 79% of revenue ($1.353 billion of $1.706 billion in Q2 2026), making the top line highly sensitive to trading volumes and volatility; a normalization in volatility could quickly erode revenue. Gross margin fell to 69.25% in Q2 2026 from 88.14% in Q1 2026, and net margin declined to 61.06% from 70.84% in Q4 2025, indicating cost or mix headwinds. The 97.2% dividend payout ratio leaves little cushion, and with revenue growth at just 0.84% YoY, any earnings miss could pressure the dividend and buyback capacity. However, the debt-to-equity of 0.119 and $4.21 billion TTM free cash flow mitigate balance-sheet risk.
Market and competitive risks include valuation compression and regulatory headwinds. At 24.43x trailing PE and 15.06x PS, CME trades at a premium to the broad financial sector and near the upper end of its historical PE range, leaving it vulnerable to multiple contraction if growth disappoints. The beta of 0.27 indicates low market correlation, but sector rotation away from defensives could still weigh on the stock. Competitive threats from electronic trading platforms and potential regulatory changes to derivatives clearing are ongoing concerns, though CME's network effects provide a strong moat. Recent news highlights a near-certain December rate hike and rising odds of multiple hikes, which could increase volatility but also raise regulatory scrutiny on derivatives markets.
Worst-case scenario: A normalization of volatility combined with a Fed pause or reversal, leading to declining trading volumes and fee compression. This could trigger a re-rating to the lower end of the historical PE band (19.3x), implying a price near $250, or a drop to the 52-week low of $218.31, representing a 28.6% decline from the current $305.71. The analyst low target of $227.00 (-25.7%) aligns with this bearish scenario. Such a decline would erase the entire 2026 gain and test the June 2026 trough, causing significant investor pain.
FAQ
The most severe risk is a normalization in trading volumes if the Fed pauses or reverses its hiking cycle, which would directly hit transaction revenue (79% of the top line). Second, margin compression is already evident: gross margin fell to 69.25% in Q2 2026 from 88.14% in Q1, and net margin declined to 61.06% from 70.84% in Q4 2025. Third, valuation risk: at 24.4x PE and 15.1x PS, the stock is vulnerable to multiple contraction, with the analyst low target of $227 implying 25.7% downside. Finally, the 97.2% dividend payout ratio limits financial flexibility if earnings decline. These risks are ranked from most to least severe.
Our 12-month forecast has three scenarios: Bull (25% probability) targeting $340-$367, driven by multiple Fed hikes and record volumes; Base (50% probability) targeting $300-$325, assuming moderate volatility and stable margins; and Bear (25% probability) targeting $218-$250, if volatility normalizes and margins contract. The base case is most likely, aligning with the analyst average target of $313.81, and assumes the Fed hikes once or twice in 2027 while trading volumes remain elevated but stable. Key to the base case is gross margin holding above 68% and no major regulatory changes.
CME appears fairly valued to slightly overvalued. Its trailing PE of 24.43x is above the 2024-2025 range (which bottomed near 19.3x) and near the upper end of its multi-year band, while the forward PE of 23.13x implies only modest earnings growth. The PS ratio of 15.06x is aggressive for a business growing revenue at under 1%, though it reflects the company's 61% net margin. Compared to exchange peers like ICE and Cboe, which trade in the low-to-mid 20s on earnings, CME's premium is justified by its liquidity moat and dividend, but the market is pricing in optimistic expectations for sustained volatility. A re-rating to the historical average PE of ~20x would imply a price near $250.
CME is a high-quality company with a wide moat, 61% net margin, and a 4% dividend yield, but at $305.71 it trades at 24.4x trailing earnings and 15.1x sales, leaving only 2.6% upside to the average analyst target of $313.81. The stock has rallied 12.89% in the past month, outperforming the S&P 500 by 13.91%, and now sits just 7.7% below its 52-week high. While the Fed rate-hike cycle supports trading volumes, revenue growth is stagnant at 0.84% and margins are compressing. For long-term income investors, it is a solid hold, but new buyers may want to wait for a pullback to the $250-$270 range for better risk/reward.
CME is best suited for long-term investment, given its low beta of 0.27, stable dividend yield of 4.00%, and wide economic moat. The stock's low volatility makes it a defensive holding, but its premium valuation and cyclical revenue limit short-term upside. Short-term traders might exploit momentum, but the recent 12.89% one-month rally raises overbought risk. For long-term investors, a minimum holding period of 3-5 years is recommended to ride out volatility cycles and benefit from dividend compounding and potential volume growth from structural increases in derivatives trading.